Bionyra Pharma competitors & alternatives

Yarrow BioscienceYARW · pharmaceuticalNew Haven, United States

65% matchPublic

pharmaceutical

Yarrow Bioscience is a U.S.-based biotechnology company focused on the development of treatments for autoimmune diseases. The company has been involved in significant pharmaceutical deals, including the acquisition of drug candidates for thyroid conditions.

Pharmaceuticals

Highlightll Pharma is a clinical-stage biopharmaceutical company headquartered in Hangzhou, China. The firm focuses on the research and development of treatments for both peripheral and central autoimmune and inflammatory diseases.

Apellis Pharmaceuticals, Inc.PharmaceuticalsUnited States

64% matchPrivate

Pharmaceuticals

Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company headquartered in Waltham, Massachusetts. Founded in 2008, the public company discovers, develops, and commercializes targeted therapeutic treatments for autoimmune and inflammatory diseases.

Pharmaceuticals

Longbio Pharma (Suzhou) Co., Ltd. operates as a clinical-stage biotechnology company. It focuses on in-house discovery and development of biopharmaceuticals targeting on allergic and autoimmune diseases. The company was founded by Heng Liu and Nai-Chau Sun on October 26, 2020 and is headquartered Suzhou, China.

Biotech, Pharma

Ilya Pharma AB is a Swedish biotechnology company developing biologic medicines based on engineered lactic-acid bacteria that deliver therapeutic proteins locally at mucosal surfaces. Its development programs have focused on local treatments for inflammatory, wound-healing, and other tissue-repair conditions.

KALM Therapeutics, Inc.Biotechnology & PharmaceuticalsUnited States

63% match

Biotechnology & Pharmaceuticals

Kalm Therapeutics, Inc. is a pre-clinical drug development company founded in 2024 and focused on pioneering a breakthrough treatment for eczema.

Reven Holdings IncPharmaceuticalsUnited States

63% matchPrivate

Pharmaceuticals

Reven Holdings Inc. is a pharmaceutical company that develops pharmacological solutions and proprietary drug formulations aimed at targeting the root cause of diseases by restoring immune system homeostasis. The company focuses on addressing inflammation-related conditions ranging from cancer to cardiovascular disease.

Pharmaceuticals

Vyome Holdings, Inc. operates as a healthcare firm currently in its clinical development phase, concentrating on the creation of innovative medicinal treatments designed to address both immuno-inflammatory conditions and infrequent disorders. Founded in 2017, the company extends its market reach throughout the United States and into global territories, headquartered in Princeton, New Jersey.

NYB Holdings LtdNYB · Biotechnology & PharmaceuticalsUnited States

62% matchPublic

Biotechnology & Pharmaceuticals

NYB Holdings Ltd operates an AI-first drug discovery and biotechnology platform that utilizes a large natural compound library and predictive modeling to identify bioactive compounds. The company develops science-backed wellness solutions for nutraceutical applications and advances high-potential drug candidates into preclinical development for the pharmaceutical industry.

Pharmaceuticals

Kalaris Therapeutics Inc. operates as a pharmaceutical enterprise. The company's core mission centers on developing innovative cell therapies. These treatments are designed to reactivate the body's inherent immunity against critical, virus-linked diseases, especially in patients with profoundly compromised immune systems.

Pharmaceuticals

Boston Pharmaceuticals is a U.S.-based clinical-stage biopharmaceutical company that acquires, develops, and advances drug candidates for serious diseases. It works with pharmaceutical and biotechnology partners to bring clinical-stage medicines toward commercialization and serves patients with significant unmet medical needs.

Pharmaceuticals

Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.